Quality Assurance Initiative on the Therapy of Bladder Cancer 2023

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00032582

Enrollment

1700

Registered

2023-10-04

Start date

2023-10-30

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C67

Interventions

Group 1: Routine treatment of patients diagnosed with non-muscle invasive bladder cancer (NMIBC) in Q4/2022-Q1/2023. Group 2: Routine treatment of patients diagnosed with muscle invasive bladder cance

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Diagnosis of non-muscle-invasive (NMIBC; T0) or metastatic (mUC, M>0) bladder carcinoma in Q4/2022-Q1/2023.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Implementation of the guideline recommendations in routine treatment	—

Secondary

Measure	Time frame
The demographic and clinical characteristics of patients without cancer-specific treatment (best supportive care).	—

Countries

Germany

Contacts

Public ContactMarkus Kerkmann

MMF Research GmbH

harnblase@mmf-research.de+49 251 928730 19

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026